



Artemisia annua and *Artemisia afra* extracts exhibit strong bactericidal activity against *Mycobacterium tuberculosis*

Maria Carla Martini^a, Tianbi Zhang^a, John T. Williams^b, Robert B. Abramovitch^b, Pamela J. Weathers^a, Scarlet S. Shell^{a,*}

^a Department of Biology and Biotechnology, Worcester Polytechnic Institute, Worcester, MA, USA

^b Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI, USA

ARTICLE INFO

Keywords:

Artemisia annua
Artemisia afra
Mycobacterium tuberculosis
Mycobacterium abscessus
 Artemisinin
 Tuberculosis

ABSTRACT

Ethnopharmacological relevance: Emergence of drug-resistant and multidrug-resistant *Mycobacterium tuberculosis* (Mtb) strains is a major barrier to tuberculosis (TB) eradication, as it leads to longer treatment regimens and in many cases treatment failure. Thus, there is an urgent need to explore new TB drugs and combinations, in order to shorten TB treatment and improve outcomes. Here, we evaluated the potential of two Asian and African traditional medicinal plants, *Artemisia annua*, a natural source of artemisinin (AN), and *Artemisia afra*, as sources of novel antitubercular agents.

Aim of the study: Our goal was to measure the activity of *A. annua* and *A. afra* extracts against Mtb as potential natural and inexpensive therapies for TB treatment, or as sources of compounds that could be further developed into effective treatments.

Materials and methods: The minimum inhibitory concentrations (MICs) of *A. annua* and *A. afra* dichloromethane extracts were determined, and concentrations above the MICs were used to evaluate their ability to kill Mtb and *Mycobacterium abscessus* *in vitro*.

Results: Previous studies showed that *A. annua* and *A. afra* inhibit Mtb growth. Here, we show for the first time that *Artemisia* extracts have a strong bactericidal activity against Mtb. The killing effect of *A. annua* was much stronger than equivalent concentrations of pure AN, suggesting that *A. annua* extracts kill Mtb through a combination of AN and additional compounds. *A. afra*, which produces very little AN, displayed bactericidal activity against Mtb that was substantial but weaker than that of *A. annua*. In addition, we measured the activity of *Artemisia* extracts against *Mycobacterium abscessus*. Interestingly, we observed that while *A. annua* is not bactericidal, it inhibits growth of *M. abscessus*, highlighting the potential of this plant in combinatory therapies to treat *M. abscessus* infections.

Conclusion: Our results indicate that *Artemisia* extracts have an enormous potential for treatment of TB and *M. abscessus* infections, and that these plants contain bactericidal compounds in addition to AN. Combination of extracts with existing antibiotics may not only improve treatment outcomes but also reduce the emergence of resistance to other drugs.

1. Introduction

3000 years after the first documented case of tuberculosis (TB) (Barberis et al., 2017) and 130 years after the discovery that *Mycobacterium tuberculosis* (Mtb) is the causative agent of TB, this disease remains one of the major worldwide health challenges. In 2018 alone, 10

million people fell ill with TB and 1.2 million died from the disease, positioning TB as one of the top 10 causes of death worldwide (WHO, 2019). A major barrier to lowering this number is the suboptimal nature of TB antibiotic therapies. Drug-sensitive TB must be treated with six months of combination therapy to prevent relapse and minimize the emergence of resistance. Drug-resistant TB requires even longer

Abbreviations: Mtb, *Mycobacterium tuberculosis*; TB, tuberculosis; AN, artemisinin; MIC, minimum inhibitory concentration; OD, optical density; CFUs, colony forming units; DCM, dichloromethane.

* Corresponding author.

E-mail address: sshell@wpi.edu (S.S. Shell).

<https://doi.org/10.1016/j.jep.2020.113191>

Received 17 April 2020; Received in revised form 26 June 2020; Accepted 15 July 2020

Available online 27 July 2020

0378-8741/© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

treatment regimens with more debilitating side effects and poorer outcomes. Thus, better drugs and combinations are needed to make TB treatment faster and less toxic. Since the late 1970s, only four drugs (linezolid, bedaquiline, delamanid, and pretomanid) have been made available as second-line antitubercular agents to treat multidrug-resistant and extensively drug-resistant TB (Keam, 2019; Lee et al., 2012; Osborne, 2013; Ryan and Lo, 2014). Despite the recent introduction of these antibiotics in TB treatment, bedaquiline and delamanid resistance have already been reported in Mtb clinical isolates (Mokrousov et al., 2019; Polsfuss et al., 2019), indicating that resistance emerges quickly and highlighting the urgent need to develop new drugs and combinations to improve TB therapy.

Recent work presented the antimalarial drug artemisinin (AN) as a promising antitubercular drug (Choi, 2017; Zheng et al., 2017). AN inhibits Mtb survival of hypoxia *in vitro* by blocking the DosRST two-component regulatory system, necessary for survival of Mtb during non-replicating persistence (Zheng et al., 2017; Zheng et al., 2019). It also has bactericidal activity against Mtb during aerated growth for reasons that are not fully elucidated but may involve lipid peroxidation (Patel et al., 2019). *Artemisia annua* is the natural source of AN, which was the scaffold for development of semi-synthetic derivatives now in widespread clinical use for treatment of malaria. Various *Artemisia* species are used in traditional medicine around the world, including use of *A. afra* in southern Africa to treat fever and cough, classic symptoms of TB (Thring and Weitz, 2006). *A. annua* is a traditional treatment for fever in China (Hsu, 2006), where TB has been endemic, and therefore a cause of fever, for at least 2000 years (Fusegawa et al., 2003). These traditional usages have prompted studies testing *Artemisia* extracts for activity against numerous pathogens and conditions, including mycobacteria in culture and in a murine model of tuberculosis (Cantrell et al., 1998; Uba et al., 2003). In addition, *A. afra*, which produces little to no AN, displayed inhibitory activity against Mtb (Mativandela, S.P.N. et al., 2008; Ntutela et al., 2009) suggesting that compounds other than AN in the extract can inhibit Mtb growth.

In the present study, we measured the ability of *A. annua* and *A. afra* extracts to kill Mtb in culture. We demonstrate that both extracts are strongly bactericidal against Mtb and produced more killing than equivalent concentrations of pure AN. We also tested the impact of these extracts on the emerging pathogen *M. abscessus* and the model organism *M. smegmatis*, and found that extracts inhibited growth but were not bactericidal at the concentrations tested.

2. Materials and methods

2.1. Strains and growth conditions

M. tuberculosis mc²6230 (Δ panCD, Δ RD1 (Sambandamurthy et al., 2006)) and virulent Erdman strains were grown in Middlebrook 7H9 supplemented with OADC (Oleic acid Albumin Dextrose Catalase, final concentrations 50 mg/L oleic acid, 5 g/L bovine serum albumin fraction V, 2 g/L dextrose, 0.85 g/L sodium chloride, and 4mg/L catalase), 0.2% glycerol, and 0.05% Tween 80. For the Mtb mc²6230 auxotrophic strain, pantothenate was added to a final concentration of 24 μ g/mL. Mtb mc²6230 and Mtb Erdman were grown in BSL-2 and BSL-3 containment, respectively, in accordance with institutionally approved standard operating procedures established for these strains. *M. smegmatis* mc²155 and *M. abscessus* ATCC_19977 (smooth morphotype) strains were grown in Middlebrook 7H9 supplemented with ADC (Albumin Dextrose Catalase, final concentrations 5 g/L bovine serum albumin fraction V, 2 g/L dextrose, 0.85 g/L sodium chloride, and 3 mg/L catalase), 0.2% glycerol and 0.05% Tween 80. *M. abscessus* was grown in BSL-2 containment in accordance with institutionally approved standard operating procedures.

Middlebrook 7H10 OADC solid media supplemented with 0.2% glycerol was used to count colony forming units (CFUs) for all strains. 24 μ g/mL pantothenate was added to Mtb mc²6230 plates and 10 μ g/mL

cycloheximide was added to Mtb Erdman plates to prevent fungal contamination.

2.2. Preparation of plant extracts

Dried leaves of *A. annua* L. SAM cultivar (voucher MASS 00317314) and *A. afra* Jacq. ex Willd. (SEN cultivar) (voucher Université de Liège LG0019529) were used and their phytochemical contents are detailed in (Weathers and Towler, 2014) and (Munyangi et al., 2018), respectively, as summarized in Supplemental Table 1. *A. annua* was propagated in-house and harvested as described (Towler and Weathers, 2015). Dried *A. afra* leaves were obtained from Guy Mergei, Université de Liège, Belgium. Sieved (2 mm) dried leaves of *A. annua* and *A. afra* were resuspended in dichloromethane (1 g dried leaves per 20 mL DCM) and extracted for 30 min in a sonicating water bath at room temperature. Leaves were extracted twice more with fresh DCM, extracts were pooled and dried under N₂ as previously detailed (Desrosiers et al., 2020; Weathers et al., 2014). AN was quantified by GC-MS using the method described in Weathers and Towler (2014) with the following modifications: ion source temperature, 230 °C; inlet, 150 °C; transfer line, 280 °C; oven temperature, 125 °C held for 1 min, then increased to 240 °C at 5 °C/min, and then increased to 300 °C at 30 °C/min. *A. annua* and *A. afra* extracts used here contained 0.82% and \leq 0.0077% AN respectively (w/w; AN/dried leaves). Dry extracts were sterilized by ethylene oxide, degassed for one day, stored at -20 °C, and later resuspended in sterile DMSO for use in experiments.

2.3. Determination of minimum inhibitory concentration (MIC)

MICs of AN and *Artemisia* extracts in Mtb strain mc²6230 were determined by resazurin microtiter assay (REMA) as previously reported (Choi, 2017) with minor modifications. Briefly, Mtb log-phase cultures were adjusted to a final OD = 0.001. Bacterial suspensions were inoculated into 96 well microtiter plate containing final concentrations of i) 1.17–600 μ g/mL pure AN or ii) *A. annua* extract containing 1.17–600 μ g/mL AN or iii) *A. afra* extract made from equivalent dry weights as the *A. annua* extract. All wells contained 2.5% DMSO and final volumes were 200 μ L. Controls consisting of 7H9 medium alone or 7H9 medium + drug/extract or 7H9 medium + bacterial culture were included. Established antimycobacterial drugs (rifampicin, isoniazid, ethambutol, streptomycin, and ofloxacin) were tested as further controls. Plates were covered with breathable paper and plastic lids, placed in plastic bags and incubated at 37 °C and 125 rpm for 7 days. After this time, 20 μ L 0.02% (w/v) resazurin solution was added to each well and incubated for 24 h. A change in color from blue to pink indicated bacterial growth. The MIC was defined as the lowest concentration of drug/extract that prevented visible color change.

2.4. Measurement of plant extract effects on mycobacterial viability

For Mtb mc²6230, *M. abscessus*, and *M. smegmatis*, log-phase cultures were sub-cultured to an OD = 0.1 and 5 mL aliquots were placed into 50 mL conical tubes. Pure drugs, *A. afra*, or *A. annua* extracts were added to achieve the desired concentrations. Cultures containing 2.5% DMSO were included as a control. Cultures were allowed to grow at 37 °C and 200 rpm for 14 days (Mtb) or 7 days (*M. abscessus* and *M. smegmatis*). Samples from all treatments were collected at time 0 and at different timepoints and serial dilutions were plated on 7H10 to calculate the number of CFUs. The number of colonies was determined after 40 days (Mtb) or 3 days (*M. abscessus* and *M. smegmatis*) of incubation at 37 °C. For Mtb Erdman strain, 30 mL of log-phase cultures were pelleted and resuspended in fresh 7H9 and 5 mL aliquots were placed in T-25 flasks and AN, *A. afra*, or *A. annua* were added. Cultures were incubated at 37 °C (+5% CO₂) in T-25 flasks without shaking for 12 days. CFUs were determined following the same procedure as with the other strains.

3. Results and discussion

In order to measure the potential of *Artemisia* extracts to kill Mtb, we first sought to determine the concentrations of pure AN and DCM extracts of *A. annua* and *A. afra* that inhibited growth of Mtb strain mc²6230. Established antimycobacterial agents were tested in parallel as controls (Fig. 1A). We found that the MIC for pure AN was 75 µg/mL. For *A. annua* the MIC was the extract from 4.81 mg of dried leaves per mL media, which resulted in 39 µg/mL of AN. For *A. afra* the MIC was also the extract from 4.81 mg of dried leaves per mL media, which contained <0.37 µg/mL of AN. These results show that *Artemisia* extracts inhibit Mtb growth to an extent that cannot be fully explained by their AN content. The MIC is used to evaluate the antimicrobial efficacy of antibiotics by measuring the bacteriostatic capability of a certain agent, but does not provide information on its bactericidal activity. Previous studies reported growth inhibition by *A. annua* and *A. afra* extracts in Mtb cultures (Cantrell et al., 1998; Mativandlela, S.P.N. et al., 2008; Ntutela et al., 2009; Uba et al., 2003). However, the bactericidal activity of these extracts has to our knowledge not yet been reported. To investigate the potential of *A. annua* extract as a bactericidal agent, we treated Mtb mc²6230 cultures with concentrations above the MIC of *A. annua* extract and found that while AN alone was bactericidal, the extract produced more killing with faster kinetics than equivalent AN concentrations alone (Fig. 1B). In addition, a two-fold increase in pure AN concentration (150 µg/mL to 300 µg/mL) did not increase killing, while an equivalent increase in *A. annua* concentration remarkably potentiated bactericidal activity against Mtb (Fig. 1B). These data suggest that *A. annua* extract kills Mtb through a combination of AN and additional compounds present in the plant extract. The bactericidal activity of the *A. annua* extract at the concentrations tested was similar to that of several established antimycobacterial drugs (Fig. 1C).

We further measured the potential of *A. afra* against Mtb mc²6230. We found that extracts of this plant exhibited bactericidal activity, although to a lesser extent than extracts of *A. annua* made from an equivalent mass of dried leaves (Fig. 1D). Given the much lower levels of AN in *A. afra* compared to *A. annua*, this result suggests that the stronger bactericidal activity of *A. annua* may be due to the combination of AN and other plant compounds. However, we cannot rule out the possibility that the difference is due to differences in other aspects of the phytochemistry of the two species. It is important to highlight that the *A. afra* extract displayed significantly greater killing than pure AN at a concentration >100-fold higher than that present in the extract, which reinforces the premise that other compounds present in *Artemisia* plants contribute to their bactericidal effects.

Previous work documenting the ability of *A. afra* extracts to inhibit mycobacterial growth also included fractionation of the plant extracts and preliminary identification of some of the constituent phytochemicals (Ntutela et al., 2009). The sesquiterpene lactones artemin and arsubin were noted in the most active fraction, suggesting they may contribute to the activity; however, this fraction contained numerous other unidentified phytochemicals as well (Ntutela et al., 2009). Several publications have implicated flavonoids as potential antimycobacterial compounds. The flavonoid 5,7,2'-trihydroxyflavone, which is similar to some flavonoids found in *Artemisia* spp., was reported to inhibit mycobacterial growth (Mativandlela, S.P. et al., 2008), while a complex mixture of flavonoids from a non-*Artemisia* source was also reported to inhibit growth of *M. tuberculosis* (Cao et al., 2019). Two *A. annua* flavonoids, naringenin and quercetin, were shown to be bactericidal to *M. smegmatis* and to inhibit activity of the *M. tuberculosis* glutamate racemase (required for peptidoglycan biosynthesis) *in vitro* (Pawar et al., 2020). We found similar total flavonoid content in *A. annua* and *A. afra* (Supplemental Table 1), consistent with the idea that flavonoids may contribute to the activity we observed, but further work is needed to determine the compositions of these pools and if any of the constituent compounds are mycobacteriocidal.

Similar bactericidal activities of *Artemisia* extracts were observed

when the virulent Mtb Erdman strain was used (Fig. 1E), although in this case AN prevented Mtb growth but did not display bactericidal activity. The differences in pure AN outcomes as well as the slightly lower killing observed for *Artemisia* extracts in Erdman compared to mc²6230 strain may be due to the different experimental conditions used in these assays (see Section 2.4). In addition, mc²6230 is a derivative of H37Rv, which has been shown to behave differently than Erdman strain in other aspects (Manabe et al., 2003; North and Izzo, 1993).

We also sought to evaluate the potential of *Artemisia* extracts against *M. abscessus*, a non-tuberculous mycobacterium causing severe infections in immunocompromised patients and whose treatment is very restricted due to the limited number of effective drugs. Interestingly, we found that pure AN and *A. afra* do not hamper *M. abscessus* growth, while *A. annua* showed bacteriostatic activity against this pathogen (Fig. 2A). *M. abscessus* is intrinsically more resistant than *M. tuberculosis* to a number of drugs, due to multiple mechanisms including the presence of enzymatic drug inactivators and differences in permeability (reviewed in (Ganapathy et al., 2019; Johansen et al., 2020)). Although bactericidal activity is highly desirable, there is debate about the extent to which bactericidal drugs are better than bacteriostatic drugs to treat clinical infections (Nemeth et al., 2015; Pankey and Sabath, 2004; Rhee and Gardiner, 2004; Wald-Dickler et al., 2018). Antibiotic efficacy *in vivo* depends on many other factors such as drug combinations, pharmacodynamics, and pharmacokinetics (Rhee and Gardiner, 2004). In addition, some antibiotics have been shown to exhibit bacteriostatic or bactericidal activity, depending on the bacterial growth phase or their interaction with other drugs (Bakker-Woudenberg et al., 2005; Lobritz et al., 2015; Yamori et al., 1992; Zhang et al., 2014). Bacteriostatic antibiotics are effective in treating *M. abscessus* and other mycobacterial infections and their use is also important in preventing emergence of drug resistance (Ferro et al., 2016; Vilchèze and Jacobs, 2012) especially when pharmacological options are limited. Thus, we propose that *A. annua* has potential to treat *M. abscessus* infections and warrants further study.

We finally investigated the effect of *A. annua* extract against *M. smegmatis*, a fast-growing non-pathogenic mycobacterium widely used as a model system to study many aspects of Mtb physiology. We found that, while growth was significantly affected, neither pure AN nor the extract have the ability to fully inhibit growth or kill this organism at the concentrations tested (Fig. 2B).

4. Conclusions

The strong bactericidal effect of *A. annua* and *A. afra* extracts against Mtb and the bacteriostatic activity of *A. annua* against *M. abscessus* point out the enormous potential of these extracts, or compounds within them, to treat mycobacterial infections. The stronger killing activity of *A. annua* compared to pure AN at equivalent concentrations and the moderate killing activity of *A. afra* suggest that other metabolites are important for these bactericidal activities, making these plants an excellent alternative to the use of pure AN. Another aspect to be considered is that using *A. annua* extracts for TB treatment could potentially increase the bioavailability of AN, as we previously observed for malaria treatment in a rat model (Desrosiers et al., 2020). In addition, the implementation of *Artemisia* extracts in treatment of Mtb and *M. abscessus* infections could slow or prevent the emergence of resistance to other drugs. Further study is needed to identify the active phytochemicals in these extracts and evaluate their potential as antitubercular drugs. Additionally, our study focused on plant extracts made with a single solvent. Other solvents should be tested to evaluate the potential of compounds that are not efficiently extracted by DCM.


Author contributions

M.C.M., S.S.S., P.J.W., and R.B.A. conceived and designed experiments. T.Z. prepared plant extracts. M.C.M., T.Z., and J.T.W. performed


A

Drug/extract	MIC ($\mu\text{g/mL}$)
Artemisinin (AN)	75
<i>A. annua</i>	39 AN*
<i>A. afra</i>	<0.37 AN*
Rifampicin	0.075
Isoniazid	0.15
Ethambutol	0.5
Streptomycin	0.04
Ofloxacin	0.5


*MIC is the extract concentration producing the indicated AN concentration.




■ 2.5% DMSO
 ▲ 150 $\mu\text{g/mL}$ AN
 ▲ 300 $\mu\text{g/mL}$ AN
 ◆ *A. annua* containing 150 $\mu\text{g/mL}$ AN
 ◆ *A. annua* containing 300 $\mu\text{g/mL}$ AN



◆ Rifampicin 0.6 $\mu\text{g/mL}$
 ◆ Isoniazid 2.4 $\mu\text{g/mL}$
 ◆ Ethambutol 2 $\mu\text{g/mL}$
 ◆ Streptomycin 2.5 $\mu\text{g/mL}$
 ◆ Ofloxacin 2.5 $\mu\text{g/mL}$



■ 2.5% DMSO
 ▲ 150 $\mu\text{g/mL}$ AN
 ◆ *A. annua* containing 150 $\mu\text{g/mL}$ AN
 ◆ *A. afra* containing <1.5 $\mu\text{g/mL}$ AN



■ 2.5% DMSO
 ▲ 150 $\mu\text{g/mL}$ AN
 ◆ *A. annua* containing 150 $\mu\text{g/mL}$ AN
 ◆ *A. afra* containing <1.5 $\mu\text{g/mL}$ AN

Fig. 1. *Artemisia* extracts exhibit strong bactericidal activity against *M. tuberculosis*. **A.** The minimum inhibitory concentrations (MICs) of AN, established TB drugs, and plant extracts were determined. For plant extracts, the AN concentrations present in the extract MICs are shown. **B.** *M. tuberculosis* mc²6230 was incubated in the presence of 150 $\mu\text{g/mL}$ or 300 $\mu\text{g/mL}$ of pure AN, or *A. annua* extract containing equivalent concentrations of AN. **C.** *M. tuberculosis* mc²6230 was incubated in the presence of several first- and second-line TB drugs. **D** and **E.** *M. tuberculosis* mc²6230 (**D**) or Erdman (**E**) were exposed to 150 $\mu\text{g/mL}$ of pure AN or *A. annua* extract containing equivalent concentrations of AN or *A. afra* at equivalent dry weight as the *A. annua* extract. Plant extract concentrations were $\sim 4\times$ their MICs. 2.5% DMSO was included as a control.




Fig. 2. *Artemisia* extracts have different impacts on *M. abscessus* and *M. smegmatis*. The strains were incubated in presence of 300 µg/mL (A) or 600 µg/mL (B) of pure AN, or *A. annua* extract containing equivalent concentrations of AN, or *A. afra* at equivalent dry weight as the *A. annua* extract. 2.5% DMSO was included as a control.

antimycobacterial activity assays. M.C.M. and S.S.S. wrote the manuscript.

Acknowledgements

This work was funded in part by R01AI116605 (to RBA) and phytochemical analysis was funded by the National Center for Complementary and Integrative Health, award number NIH-2R15AT008277-02 (to PW). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Complementary and Integrative Health or the National Institutes of Health. We thank Melissa Towler for assistance with quantification of the artemisinin content in plant extracts. We thank Guy Mergei for providing *A. afra* plant material. We thank members of the Shell and Weathers labs for technical assistance and helpful discussions.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jep.2020.113191>.

References

- Bakker-Woudenberg, I.A., van Vianen, W., van Soelingen, D., Verbrugh, H.A., van Agtmael, M.A., 2005. Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase, and their use in combination. *Antimicro. Agent Chem.* 49 (6), 2387–2398.
- Barberis, I., Bragazzi, N.L., Galluzzo, L., Martini, M., 2017. The history of tuberculosis: from the first historical records to the isolation of Koch's bacillus. *J Prev Med Hyg* 58 (1), E9–E12.
- Cantrell, C., Fischer, N., Urbatsch, L., McGuire, M., Franzblau, S., 1998. Antimycobacterial crude plant extracts from south, central, and North America. *Phytomedicine* 5 (2), 137–145.
- Cao, R., Teskey, G., Islamoglu, H., Gutierrez, M., Salaiz, O., Munjal, S., Fraix, M.P., Sathananthan, A., Nieman, D.C., Venketaraman, V., 2019. Flavonoid mixture inhibits *Mycobacterium tuberculosis* survival and infectivity. *Molecules* 24 (5).
- Choi, W.H., 2017. Novel pharmacological activity of artesunate and artemisinin: their potential as anti-tubercular agents. *J. Clin. Med.* 6 (3), 30.
- Desrosiers, M.R., Mittelman, A., Weathers, P.J., 2020. Dried leaf *Artemisia annua* improves bioavailability of artemisinin via cytochrome P450 inhibition and enhances artemisinin efficacy downstream. *Biomolecules* 10 (2), 254.
- Ferro, B.E., Meletiadis, J., Wattenberg, M., De Jong, A., van Soelingen, D., Mouton, J.W., van Ingen, J., 2016. Clofazimine prevents the regrowth of *Mycobacterium abscessus* and *Mycobacterium avium* type strains exposed to amikacin and clarithromycin. *Antimicro. Agent Chem.* 60 (2), 1097–1105.
- Fusegawa, H., Wang, B.H., Sakurai, K., Nagasawa, K., Okauchi, M., Nagakura, K., 2003. Outbreak of tuberculosis in a 2000-year-old Chinese population. *Kansenshogaku Zasshi* 77 (3), 146–149.

- Ganapathy, U.S., Dartois, V., Dick, T., 2019. Repositioning rifamycins for *Mycobacterium abscessus* lung disease. *Expert Opin. Drug Discov.* 14 (9), 867–878.
- Hsu, E., 2006. The history of qing hao in the Chinese materia medica. *Trans. R. Soc. Trop. Med. Hyg.* 100 (6), 505–508.
- Johansen, M.D., Herrmann, J.L., Kremer, L., 2020. Non-tuberculous mycobacteria and the rise of *Mycobacterium abscessus*. *Nat. Rev. Microbiol.* 18 (7), 392–407.
- Keam, S.J., 2019. Pretomanid: first approval. *Drugs* 79 (16), 1797–1803.
- Lee, M., Lee, J., Carroll, M.W., Choi, H., Min, S., Song, T., Via, L.E., Goldfeder, L.C., Kang, E., Jin, B., Park, H., Kwak, H., Kim, H., Jeon, H.S., Jeong, I., Joh, J.S., Chen, R. Y., Olivier, K.N., Shaw, P.A., Follmann, D., Song, S.D., Lee, J.K., Lee, D., Kim, C.T., Dartois, V., Park, S.K., Cho, S.N., Barry 3rd, C.E., 2012. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. *N. Engl. J. Med.* 367 (16), 1508–1518.
- Lobritz, M.A., Belenky, P., Porter, C.B., Gutierrez, A., Yang, J.H., Schwarz, E.G., Dwyer, D.J., Khalil, A.S., Collins, J.J., 2015. Antibiotic efficacy is linked to bacterial cellular respiration. *Proc. Natl. Acad. Sci. Unit. States Am.* 112 (27), 8173–8180.
- Manabe, Y.C., Dannenberg, A.M., Tyagi, S.K., Hatem, C.L., Yoder, M., Woolwine, S.C., Zook, B.C., Pitt, M.L.M., Bishai, W.R., 2003. Different strains of *Mycobacterium tuberculosis* cause various spectrums of disease in the rabbit model of tuberculosis. *Infect. Immun.* 71 (10), 6004–6011.
- Mativandla, S.P., Meyer, J.J., Hussein, A.A., Houghton, P.J., Hamilton, C.J., Lall, N., 2008a. Activity against *Mycobacterium smegmatis* and *M. tuberculosis* by extract of South African medicinal plants. *Phytother Res.* 22 (6), 841–845.
- Mativandla, S.P.N., Meyer, J.J.M., Hussein, A.A., Houghton, P.J., Hamilton, C.J., Lall, N., 2008b. Activity against *Mycobacterium smegmatis* and *M. tuberculosis* by extract of South African medicinal plants. *Phytother Res.: Int. J. Devoted Pharm. Toxicol. Eval. Nat. Product Derivat.* 22 (6), 841–845.
- Mokrousov, I., Akhmedova, G., Plev, D., Molchanov, V., Vyazovaya, A., 2019. Acquisition of bedaquiline resistance by extensively drug-resistant *Mycobacterium tuberculosis* strain of Central Asian Outbreak clade. *Clin. Microbiol. Infect.* 25 (10), 1295–1297.
- Munyangi, J., Cornet-Vernet, L., Idumbo, M., Lu, C., Lutgen, P., Perronne, C., Ngombe, N., Bianga, J., Mupenda, B., Lalukala, P., Mergeai, G., Mumba, D., Towler, M., Weathers, P., 2018. Effect of *Artemisia annua* and *Artemisia afra* tea infusions on schistosomiasis in a large clinical trial. *Phytomedicine* 51, 233–240.
- Nemeth, J., Oesch, G., Kuster, S.P., 2015. Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis. *J. Antimicrob. Chemother.* 70 (2), 382–395.
- North, R.J., Izzo, A.A., 1993. Mycobacterial virulence. Virulent strains of *Mycobacteria tuberculosis* have faster in vivo doubling times and are better equipped to resist growth-inhibiting functions of macrophages in the presence and absence of specific immunity. *J. Exp. Med.* 177 (6), 1723–1733.
- Ntutela, S., Smith, P., Matika, L., Mukinda, J., Arendse, H., Allie, N., Estes, D.M., Mabusela, W., Folb, P., Steyn, L., 2009. Efficacy of *Artemisia afra* phytotherapy in experimental tuberculosis. *Tuberculosis* 89, S33–S40.
- Osborne, R., 2013. First Novel Anti-tuberculosis Drug in 40 Years. Nature Publishing Group.
- Pankey, G., Sabath, L., 2004. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. *Clin. Infect. Dis.* 38 (6), 864–870.
- Patel, Y.S., Mistry, N., Mehra, S., 2019. Repurposing artemisinin as an anti-mycobacterial agent in synergy with rifampicin. *Tuberculosis* 115, 146–153.
- Pawar, A., Jha, P., Chopra, M., Chaudhry, U., Saluja, D., 2020. Screening of natural compounds that targets glutamate racemase of *Mycobacterium tuberculosis* reveals the anti-tubercular potential of flavonoids. *Sci. Rep.* 10 (1), 949.

- Polsfuss, S., Hofmann-Thiel, S., Merker, M., Krieger, D., Niemann, S., Rüssmann, H., Schönfeld, N., Hoffmann, H., Kranzer, K., 2019. Emergence of low-level delamanid and bedaquiline resistance during extremely drug-resistant tuberculosis treatment. *Clin. Infect. Dis.* 69 (7), 1229–1231.
- Rhee, K.Y., Gardiner, D.F., 2004. Clinical relevance of bacteriostatic versus bactericidal activity in the treatment of gram-positive bacterial infections. *Clin. Infect. Dis.* 39 (5), 755–756.
- Ryan, N.J., Lo, J.H., 2014. Delamanid: first global approval. *Drugs* 74 (9), 1041–1045.
- Sambandamurthy, V.K., Derrick, S.C., Hsu, T., Chen, B., Larsen, M.H., Jalapathy, K.V., Chen, M., Kim, J., Porcelli, S.A., Chan, J., Morris, S.L., Jacobs, J., William, R., 2006. *Mycobacterium tuberculosis* Δ RD1 Δ panCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. *Vaccine* 24 (37–39), 6309–6320.
- Thring, T.S., Weitz, F.M., 2006. Medicinal plant use in the bredasdorp/elim region of the southern overberg in the western cape province of South Africa. *J. Ethnopharmacol.* 103 (2), 261–275.
- Towler, M.J., Weathers, P.J., 2015. Variations in key artemisinic and other metabolites throughout plant development in *Artemisia annua* L. for potential therapeutic use. *Ind. Crop. Prod.* 67, 185–191.
- Uba, A., Ibrahim, K., Agbo, E., Makinde, A., 2003. In vitro inhibition of *Mycobacterium smegmatis* and *Mycobacterium tuberculosis* by some Nigerian Medicinal Plants. *East Central African J. Pharm. Sci.* 6 (1), 15–19.
- Vilchèze, C., Jacobs, W.R., 2012. The combination of sulfamethoxazole, trimethoprim, and isoniazid or rifampin is bactericidal and prevents the emergence of drug resistance in *Mycobacter. Tuber. Antimicro. Agents Chemother.* 56 (10), 5142–5148.
- Wald-Dickler, N., Holtom, P., Spellberg, B., 2018. Busting the myth of “static vs cidal”: a systemic literature review. *Clin. Infect. Dis.* 66 (9), 1470–1474.
- Weathers, P.J., Jordan, N.J., Lasin, P., Towler, M.J., 2014. Simulated digestion of dried leaves of *Artemisia annua* consumed as a treatment (pACT) for malaria. *J. Ethnopharmacol.* 151 (2), 858–863.
- Weathers, P.J., Towler, M.J., 2014. Changes in key constituents of clonally propagated *Artemisia annua* L. during preparation of compressed leaf tablets for possible therapeutic use. *Ind. Crop. Prod.* 62, 173–178.
- WHO, 2019. Global Tuberculosis Report.
- Yamori, S., Ichiyama, S., Shimokata, K., Tsukamura, M., 1992. Bacteriostatic and bactericidal activity of antituberculosis drugs against *Mycobacterium tuberculosis*, *Mycobacterium avium-Mycobacterium intracellulare* complex and *Mycobacterium kansasii* in different growth phases. *Microbiol. Immunol.* 36 (4), 361–368.
- Zhang, M., Sala, C., Dhar, N., Vocat, A., Sambandamurthy, V.K., Sharma, S., Marriner, G., Balasubramanian, V., Cole, S.T., 2014. In vitro and in vivo activities of three oxazolidinones against nonreplicating *Mycobacterium tuberculosis*. *Antimicro. Agent Chem.* 58 (6), 3217–3223.
- Zheng, H., Colvin, C.J., Johnson, B.K., Kirchoff, P.D., Wilson, M., Jorgensen-Muga, K., Larsen, S.D., Abramovitch, R.B., 2017. Inhibitors of *Mycobacterium tuberculosis* DosRST signaling and persistence. *Nat. Chem. Biol.* 13 (2), 218.
- Zheng, H., Williams, J.T., Alewi, B., Ellsworth, E., Abramovitch, R.B., 2020. Inhibiting *Mycobacterium tuberculosis* DosRST Signaling by Targeting Response Regulator DNA Binding and Sensor Kinase Heme. *ACS Chem Biol* 15 (1), 52–62. <https://doi.org/10.1021/acscchembio.8b00849>.